{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:48:13Z","timestamp":1792622893322,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40264-020-00968-7","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T10:25:48Z","timestamp":1593685548000},"page":"1121-1131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting"],"prefix":"10.1007","volume":"43","author":[{"given":"Eiko","family":"Iwasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fujiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-2810","authenticated-orcid":false,"given":"Henric","family":"Taavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Niklas","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-381X","authenticated-orcid":false,"given":"Rika","family":"Wakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"968_CR1","unstructured":"Pharmaceutical Affairs Law [in Japanese]. Law number: Act No. 145 of 1960, last version: Amendment of Act No. 108 of 2016. https:\/\/elaws.e-gov.go.jp\/search\/elawsSearch\/elaws_search\/lsg0500\/detail?lawId=335AC0000000145. Accessed 6 Apr 2020."},{"key":"968_CR2","unstructured":"Good Vigilance Practice ministerial ordinance [in Japanese]. Law number: Act No. 135 of 2004, last version: Amendment of Act No. 124 of 2017. https:\/\/elaws.e-gov.go.jp\/search\/elawsSearch\/elaws_search\/lsg0500\/detail?lawId=416M60000100135&openerCode=1. Accessed 6 Apr 2020."},{"issue":"12","key":"968_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40264-019-00861-y","volume":"42","author":"R Wakao","year":"2019","unstructured":"Wakao R, Taavola H, Sandberg L, Iwasa E, Soejima S, Chandler R, et al. Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports. Drug Saf. 2019;42(12):1487\u201398. https:\/\/doi.org\/10.1007\/s40264-019-00861-y.","journal-title":"Drug Saf"},{"issue":"11","key":"968_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/pds.1071","volume":"14","author":"LC Koo","year":"2005","unstructured":"Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F, Wolf MK, et al. National differences in reporting \u2018pneumonia\u2019 and \u2018pneumonia interstitial\u2019: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf. 2005;14(11):775\u201387. https:\/\/doi.org\/10.1002\/pds.1071.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"968_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/pds.3998","volume":"25","author":"L Pinheiro","year":"2016","unstructured":"Pinheiro L, Blake K, Januskiene J, Yue QY, Arlett P. Geographical variation in reporting interstitial lung disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance. Pharmacoepidemiol Drug Saf. 2016;25(6):705\u201312. https:\/\/doi.org\/10.1002\/pds.3998.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"968_CR6","first-page":"405","volume":"50","author":"A Azuma","year":"2007","unstructured":"Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Jpn Med Assoc J. 2007;50(5):405\u201311.","journal-title":"Jpn Med Assoc J"},{"issue":"12","key":"968_CR7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case\u2013control study. Am J Respir Crit Care Med. 2008;177(12):1348\u201357. https:\/\/doi.org\/10.1164\/rccm.200710-1501OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"968_CR8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","volume":"10","author":"MH Cohen","year":"2004","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10(4):1212\u20138.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"968_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","volume":"7","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356. https:\/\/doi.org\/10.3390\/jcm7100356.","journal-title":"J Clin Med"},{"issue":"11","key":"968_CR10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/pds.4252","volume":"26","author":"C Ishiguro","year":"2017","unstructured":"Ishiguro C, Misu T, Iwasa E, Izawa T. Analysis of safety-related regulatory actions by Japan\u2019s pharmaceutical regulatory agency. Pharmacoepidemiol Drug Saf. 2017;26(11):1314\u201320. https:\/\/doi.org\/10.1002\/pds.4252.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"968_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-020-00130-6","author":"O Lagerlund","year":"2020","unstructured":"Lagerlund O, Strese S, Fladvad M, Lindquist M. WHODrug: a global, validated and updated dictionary for medicinal information. Ther Innov Regul Sci. 2020. https:\/\/doi.org\/10.1007\/s43441-020-00130-6.","journal-title":"Ther Innov Regul Sci"},{"issue":"10","key":"968_CR12","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/pds.4285","volume":"26","author":"K Juhlin","year":"2017","unstructured":"Juhlin K, Star K, Noren GN. A method for data-driven exploration to pinpoint key features in medical data and facilitate expert review. Pharmacoepidemiol Drug Saf. 2017;26(10):1256\u201365. https:\/\/doi.org\/10.1002\/pds.4285.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"968_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","volume":"39","author":"RR Shah","year":"2016","unstructured":"Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf. 2016;39(11):1073\u201391. https:\/\/doi.org\/10.1007\/s40264-016-0450-9.","journal-title":"Drug Saf"},{"key":"968_CR14","unstructured":"AstraZeneca KK. Final report of use-results survey of tagrisso. 2019. https:\/\/www.pmda.go.jp\/files\/000228398.pdf. Accessed 6 June 2020."},{"issue":"8","key":"968_CR15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","volume":"7","author":"K Nakagawa","year":"2012","unstructured":"Nakagawa K, Kudoh S, Ohe Y, Johkoh T, Ando M, Yamazaki N, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol. 2012;7(8):1296\u2013303. https:\/\/doi.org\/10.1097\/JTO.0b013e3182598abb.","journal-title":"J Thorac Oncol"},{"key":"968_CR16","unstructured":"Saijo N, Kato H, Kudo S, Tada H, Tamura T, Hayakawa K, et al. Guideline for using gefitinib [in Japanese]. 2005. https:\/\/www.pmda.go.jp\/files\/000145266.pdf. Accessed 6 June 2020."},{"key":"968_CR17","unstructured":"MHLW. Precautions relating to interstitial lung disease during administration of epidermal growth factor receptor tyrosine kinase inhibitors [in Japanese]. MHLW, Tokyo. 2016. https:\/\/www.pmda.go.jp\/files\/000213244.pdf. Accessed 6 June 2020."},{"key":"968_CR18","unstructured":"MHLW. Pharmaceuticals and medical devices safety information no. 336. September 2016. https:\/\/www.pmda.go.jp\/files\/000214024.pdf. Accessed 6 June 2020."},{"key":"968_CR19","unstructured":"MHLW. Notification about interim report of the all-case survey of osimertinib [in Japanese]. MHLW, Tokyo. 2018. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-11120000-Iyakushokuhinkyoku\/0000192974.pdf. Accessed 6 June 2020."},{"key":"968_CR20","unstructured":"MHLW. Notification about osimertinib use-results survey [in Japanese]. MHLW, Tokyo. 2019. https:\/\/www.mhlw.go.jp\/content\/11120000\/000484135.pdf. Accessed 6 June 2020."},{"issue":"4","key":"968_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507\u201316. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.013.","journal-title":"Ann Oncol"},{"issue":"8","key":"968_CR22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4526.","journal-title":"JAMA Oncol"},{"issue":"5","key":"968_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","volume":"30","author":"AJ Schoenfeld","year":"2019","unstructured":"Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30(5):839\u201344. https:\/\/doi.org\/10.1093\/annonc\/mdz077.","journal-title":"Ann Oncol"},{"issue":"5","key":"968_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.resinv.2018.06.002","volume":"56","author":"S Saito","year":"2018","unstructured":"Saito S, Lasky JA, Hagiwara K, Kondoh Y. Ethnic differences in idiopathic pulmonary fibrosis: the Japanese perspective. Respir Investig. 2018;56(5):375\u201383. https:\/\/doi.org\/10.1016\/j.resinv.2018.06.002.","journal-title":"Respir Investig"},{"issue":"8","key":"968_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/annrheumdis-2018-214263","volume":"78","author":"N Namba","year":"2019","unstructured":"Namba N, Kawasaki A, Sada KE, Hirano F, Kobayashi S, Yamada H, et al. Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis. 2019;78(8):1144\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214263.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"968_CR26","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"PA Juge","year":"2018","unstructured":"Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1801562.","journal-title":"N Engl J Med"},{"issue":"6","key":"968_CR27","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00280-016-3026-6","volume":"77","author":"M Nishimura","year":"2016","unstructured":"Nishimura M, Toyoda M, Takenaka K, Imamura Y, Chayahara N, Kiyota N, et al. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2016;77(6):1165\u201370. https:\/\/doi.org\/10.1007\/s00280-016-3026-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"968_CR28","doi-asserted-by":"publisher","first-page":"e0223371","DOI":"10.1371\/journal.pone.0223371","volume":"14","author":"C Udagawa","year":"2019","unstructured":"Udagawa C, Horinouchi H, Shiraishi K, Kohno T, Okusaka T, Ueno H, et al. Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PLoS ONE. 2019;14(10):e0223371. https:\/\/doi.org\/10.1371\/journal.pone.0223371.","journal-title":"PLoS ONE"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00968-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:13:42Z","timestamp":1625181222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00968-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"2 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No specific grant from any funding agency in the public, commercial, or not-for profit sectors was received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eiko Iwasa, Yu Fujiyoshi, Yuki Kubota, Ryota Kimura, Rebecca E. Chandler, Henric Taavola, G. Niklas Nor\u00e9n, and Rika Wakao have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Japanese datasets analyzed during the current study are available in the JADER repository ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}}]}}